Join to View Full Profile
1000 E 101st TerKansas City, MO 64131
Phone+1 913-574-2438
Fax+1 913-588-3987
Dr. Noaiseh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ghaith Noaiseh is a rheumatologist in Kansas City, KS and is affiliated with UPMC Presbyterian. He received his medical degree from University of Tichreen Faculty of Medicine and has been in practice 15 years. He is experienced in sjogren's syndrome and clinical trials in sjogren's syndrome and sle.
Education & Training
University of Pennsylvania Health SystemFellowship, Rheumatology, 2010 - 2012
St Vincent Charity Medical CenterResidency, Internal Medicine, 2004 - 2007
University of Tichreen Faculty of MedicineClass of 2002
Certifications & Licensure
KS State Medical License 2019 - 2026
MO State Medical License 2019 - 2026
OH State Medical License 2004 - 2021
PA State Medical License 2010 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease.Anahita Deboo, Robert Fox, Katherine M Hammitt, Julie Frantsve-Hawley, Matthew C Baker
Arthritis Care & Research. 2025-12-01 - 3 citationsEfficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial.Ghaith Noaiseh, Kathy L Sivils, Kim Campbell, Jada Idokogi, Kim Hung Lo
Lancet. 2025-11-22 - Plain language summary: treatment of Sjögren's disease with dazodalibep.E William St Clair, Alan N Baer, Wan-Fai Ng, Ghaith Noaiseh, Teresa K Tarrant
Immunotherapy. 2025-10-01
Press Mentions
Published in the Lancet: Nipocalimab Significantly Decreased Sjögren's Disease (SjD) Activity and Severity Through Substantial Reduction in Sjögren's-related AutoantibodiesOctober 24th, 2025- FcRn Blocker Nipocalimab Improves Disease Activity in Sjögren’s DiseaseNovember 25th, 2024
- FDA Approvals, Mixed Efficacy Results Mark FcRn Blockade Pipeline in RheumatologyFebruary 10th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
